Loading stock data…
Indivior Pharmaceuticals (INDV)
$41.83+0.54 (+1.31%)
Market ClosedLast close Jun 26
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Indivior Pharmaceuticals, Inc. in the Healthcare sector is trading at $41.83 with a market capitalization of $4.5B. Wall Street consensus targets $50.71 (7 analysts), implying a +21.2% move over the next 12 months. The stock is currently near its 52-week high of $42.81, remaining 29.0% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +21.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $317.00M↓ | $358.00M↑ | $314.00M↑ | $302.00M↑ | $266.00M |
| Gross Profit | $277.00M↓ | $291.00M↑ | $231.00M↓ | $250.00M↑ | $222.00M |
| Operating Income | $137.00M↑ | $83.00M↑ | $44.00M↓ | $71.00M↑ | $67.00M |
| Net Income | $89.00M↓ | $102.00M↑ | $42.00M↑ | $18.00M↓ | $47.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Can...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.50B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-174.31%
Volume
Today's trading volume
5.61M
Recent News
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati
Ionis grants Recordati ex-U.S. rights to zilganersen for Alexander disease while retaining U.S. commercialization and securing upfront and royalty payments.
Kymera Jumps 17% on Early Enrollment Completion in Skin Disease Study
KYMR stock soars 17% as investor optimism was lifted following early enrollment completion in mid-stage AD study, moving KT-621 top-line data to year-end 2026.
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
IBD 50 Stock Indivior Breaks Out Amid Big Fund Ownership Expansion, Strong Profit Prospects
Indivior, which is adding big gains this week, deserves attention as it meets practically every factor in the stock picking methodology of Investor's Business Daily. Thus it serves as Thursday's IBD 50 Stocks To Watch pick. Also this week, Indivior's relative strength line has bolted to new high ground.
Reasons Why Investors Should Consider Betting on Indivior Stock
INDV's Sublocade reaches 500,000+ U.S. patients. Management expects faster 2026 growth through cost optimization and strong execution.